You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Ibrahim Alkatout -- 1796 2022-10-17 12:06:55 |
2 format change Peter Tang -2 word(s) 1794 2022-10-18 02:49:11 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Ghasemi, F.;  Alemzadeh, E.;  Allahqoli, L.;  Alemzadeh, E.;  Mazidimoradi, A.;  Salehiniya, H.;  Alkatout, I. MicroRNAs Dysregulation for Early Diagnosis of Endometriosis. Encyclopedia. Available online: https://encyclopedia.pub/entry/29695 (accessed on 05 December 2025).
Ghasemi F,  Alemzadeh E,  Allahqoli L,  Alemzadeh E,  Mazidimoradi A,  Salehiniya H, et al. MicroRNAs Dysregulation for Early Diagnosis of Endometriosis. Encyclopedia. Available at: https://encyclopedia.pub/entry/29695. Accessed December 05, 2025.
Ghasemi, Fahimeh, Effat Alemzadeh, Leila Allahqoli, Esmat Alemzadeh, Afrooz Mazidimoradi, Hamid Salehiniya, Ibrahim Alkatout. "MicroRNAs Dysregulation for Early Diagnosis of Endometriosis" Encyclopedia, https://encyclopedia.pub/entry/29695 (accessed December 05, 2025).
Ghasemi, F.,  Alemzadeh, E.,  Allahqoli, L.,  Alemzadeh, E.,  Mazidimoradi, A.,  Salehiniya, H., & Alkatout, I. (2022, October 17). MicroRNAs Dysregulation for Early Diagnosis of Endometriosis. In Encyclopedia. https://encyclopedia.pub/entry/29695
Ghasemi, Fahimeh, et al. "MicroRNAs Dysregulation for Early Diagnosis of Endometriosis." Encyclopedia. Web. 17 October, 2022.
MicroRNAs Dysregulation for Early Diagnosis of Endometriosis
Edit
This entry is adapted from the peer-reviewed paper 10.3390/biomedicines10102558

Endometriosis is a benign chronic disease in women that is characterized by the presence of active foci of the endometrium or endometrial tissue occurring outside of the uterus. The disease causes disabling symptoms such as pelvic pain and infertility, which negatively affect a patient’s quality of life. In addition, endometriosis imposes an immense financial burden on the healthcare system. Laparoscopy is the gold standard for diagnosing the disease because other non-invasive diagnostic tests have less accuracy. In addition, other diagnostic tests have low accuracy. Numerous researchers have suggested miRNAs as potential biomarkers for endometriosis diagnosis due to their specificity and stability.

endometriosis miRNAs biomarker mir-200 family

1. Introduction

Endometriosis is an estrogen-dependent gynecological disease that manifests as endometrial tissue that occurs outside of its original location, i.e., in the uterus’s muscular layer, other genitals and their surroundings, or even in locations outside of the body’s genital organs [1]. Endometrial foci can develop outside of the uterus in places including the peritoneum, the bladder, the ureters, or the ovaries [2]. Functionally, the ectopic endometrial tissue is similar to the eutopic endometrium. Ovarian cysts, peritoneal endometriosis, and nodules of deeply infiltrating endometriosis (DIE) in the vaginal-rectal septum or the gut are the three most common kinds of endometriosis [3]. The specific etiology of endometriosis has not yet been determined. Congenital, allergic, epigenetic, environmental, and autoimmune are some of the etiological factors that are listed [4].
One very typical symptom of endometriosis is infertility. Infertility can affect approximately 35–50% of women who suffer from endometriosis [5]. Up to 50% of women with pelvic pain and/or infertility and 10–15% of reproductive-aged women have endometriosis [6]. Endometriosis symptoms include infertility, dysmenorrhea, pelvic pain, dyspareunia, mittelschmerz, back pain, dysuria, dyschezia, abundant irregular menstruation, gastrointestinal problems (diarrhea or constipation), hematochezia, and chronic fatigue [7][8][9]. Adhesions, organ damage, and fibrosis are the main causes of infertility and pain in endometriosis’ severe phases [10]. Endometriosis can have an impact on a woman’s general health as well as her mental and social well-being [11][12][13]. The quality of life is significantly reduced as a result [11][14].
Endometriosis is a disorder that is highly underdiagnosed and undertreated, with a long lag time of 8–12 years between the symptom onset and a definitive diagnosis [15][16]. Since most symptoms are non-specific, there are currently no non-invasive diagnostic techniques that can accurately identify a problem that can definitively diagnose a condition [17]. However, a thorough medical history, a gynecological examination using a speculum, a bimanual pelvic examination, imaging techniques [16], ultrasonography [18], three- and four-dimensional transperineal ultrasound [19], magnetic resonance imaging (MRI)), and biochemical tests are beneficial in the early diagnosis of the disease [4][20].
Endometriosis can now only be definitively diagnosed through histological evaluation of ectopic implants retrieved through invasive surgical or laparoscopic procedures [10][21], as the origin is unknown and there are discrepancies in its diagnosis and therapy [22].
Several markers have been studied for the diagnosis of endometriosis, including cancer antigen (CA)-125 [23][24], CA-72-4 [25], CA 15-3 and CA 19-9 [26], enolase/creatine [27], protein PP14 [28], and TATI [29], but they have been shown to be insufficient to replace surgery and histology due to low sensitivity in the detection of endometriosis [26].

2. MicroRNAs as a New Diagnostic Biomarker for Endometriosis

miRNAs are evolutionary conserved, non-coding, regulatory RNA molecules with 21–25 nucleotides (nt) in length that target 3´-untranslated region (3´-UTR) of specific mRNAs and promote mRNA degradation and suppress translation [30][31][32][33]. MicroRNAs participate in RNA silencing and regulation of gene expression post-transcriptionally [31][32]. It is estimated that about 2588 miRNAs regulate the expression of over 60% of all genes in humans [34]. MicroRNAs play vital roles in a wide variety of physiological and pathological processes including, cell-to-cell signalling, cell division, apoptosis, proliferation, cell differentiation, and stress response. The aberrant expression of miRNAs is associated with the pathogenesis and progression of numerous diseases such as cancer, cardiovascular, inflammatory, and gynecological conditions [30][31][35]. A systemic review assessed that several studies have focused on the precise regulation of gene expression by miRNAs [36]. The regulation of gene expression by miRNA has occurred through a fine-tuned and complex network in which a single miRNA modulates over a hundred mRNAs and each transcript might be targeted by several miRNAs [32][36][37].
miRNA genes are mostly located within the intronic regions of protein-coding genes and transcribed as long primary miRNAs (pri-miRNAs) by RNA polymerase II (RNA PolII) [37][38]. The pri-miRNAs are then processed in the nucleus by Drosha endonuclease and its cofactor DiGeorge Syndrome Critical Region 8 (DGCR8), and cleaved into precursor miRNAs (pre-miRNA) [38][39]. Next, exportin-5 transports pre-miRNAs from the nucleus to the cytoplasm, where they are processed by RNase III Dicer to produce 21–24 nt long double-stranded-miRNAs, which are then unwound to single-stranded molecules by helicases [37][38][40]. The mature single-stranded miRNAs are subsequently assembled into the RNA-induced silencing complex (RISC) and target mRNAs with complementary sequences to regulate gene expression post-translationally [37]. A schematic view of miRNA biogenesis is depicted in Figure 1.
Figure 1. The schematic view of miRNA biogenesis.
MicroRNAs are mainly transcribed by RNA polymerase II as long pri-miRNAs, which are then processed in the nucleus by Drosha endonuclease and its cofactor DiGeorge Syndrome Critical Region 8 (DGCR8). Next, exportin-5 transports the resulting pre-miRNA to the cytoplasm where a complex of Dicer enzyme and TAR RNA binding protein (TRBP) creates a double-stranded miRNA which is unwound to a mature single-stranded miRNA. Finally, the single-stranded miRNA is assembled into a miRNA-induced silencing effector complex (RISC), leading to complementary mRNA sequence and regulating gene expression post-translationally [37][41].
Furthermore, miRNAs can be released from cells into the circulation and other biological fluids such as urine, saliva, spinal fluid, follicular fluid, and menstrual blood via a variety of carriers, including exosomes, which confer significant stability against ribonucleases (RNAses) [36]. Circulating miRNAs serve as messengers. They are delivered to distant cells by exosomes so that they can modulate the translation in the recipient cells [36][42]. The biogenesis and expression of miRNAs are tightly regulated and alteration in miRNA expression has been observed in many diseases, implying that aberrant miRNAs expression is associated with some alteration in healthy physiological conditions and leads to diseases such as gynecological conditions [31][36]. Different studies have linked the dysregulation of miRNA expression to the pathogenesis of endometriosis [32][33][43].
In 2009, Ohlsson et al. carried out a miRNA microarray analysis to determine the miRNA expression profile of ectopic endometrial lesions and eutopic endometrium tissues obtained from endometriosis-afflicted women. They found that 22 miRNAs were expressed differently in ectopic and eutopic endometrial tissue samples, with 14 miRNAs being upregulated and eight miRNAs being downregulated [44].
Some dysregulated miRNAs have been proposed to modulate the genes that are implicated in the processes necessary for endometriosis development and progression, like inflammation, angiogenesis, and immunological modulations [33][43].
Braza-Boils et al. (2014) identified the endometriosis-related miRNA expression profiles in endometrial tissues and endometriotic lesions taken from the same patients. They also looked at the relationship between the miRNA expression levels and some important angiogenic and fibrinolytic factors in endometrial tissues and three types of endometriotic lesions [43]. According to their findings, miR-202-3p, miR-424-5p, miR-449b-3p, and miR-556-3p were significantly downregulated, and VEGF-A and uPA were upregulated in patient endometrial tissue compared to the healthy endometrium. They also noticed that miR-449b-3p was significantly downregulated in ovarian endometrioma compared to endometrium removed from both patients and controls, while PAI-1 and the angiogenic inhibitor TSP-1 were both upregulated. Additionally, they found that miR-424-5p expression was inversely correlated with the protein levels of VEGF-A in patient endometrial tissue and miR-449b-3p expression was inversely correlated with the protein levels of TSP-1 in ovarian endometrioma [43].
Gao et al. in 2019, used quantitative polymerase chain reaction (qRT-PCR) to determine the expression levels of mir-451 in cultured primary cells, obtained from ectopic and eutopic endometrial tissues, pathologic tissues of endometriosis patients, and healthy women. MiR-451 expression was shown to be decreased in eutopic endometrial tissues taken from endometriosis patients compared with the control. Furthermore, they observed that overexpression of miR-451 induced apoptosis and hindered cell proliferation in cultured eutopic cells whereas siRNA-mediated miR-451 knockdown reversed these effects [45].
Aberrant expression of miRNAs has also been well documented in the circulation and other body fluids of endometriosis patients, suggesting that these molecules can serve as beneficial diagnostic biomarkers for the non-invasive and early detection of endometriosis, leading to earlier medical interventions [31][33][40][46][47]. However, the issues arose as a result of inconsistencies or divergences in the findings [33]. Different studies have introduced different sets of miRNAs with different expression patterns as potential biomarkers of endometriosis. At present, there is no validated miRNA-base diagnosis test for the non-invasive detection of endometriosis. However, the potential use of circulating miRNAs as non-invasive biomarkers for endometriosis has been considered as an ongoing research area and its diagnostic and therapeutic implications are being extensively studied [31][33][35][48][49].
In 2013, Wang et al. performed a circulating miRNA array analysis and identified different miRNA expression patterns in the serum of the endometriosis patients compared with the control [50]. They reported that the relative expression levels of miR-122 and miR-199a in serum samples from endometriosis patients were higher than the control, while the expression levels of some other miRNAs such as miR-145*, miR-141*, miR-542-3p, and miR-9* were lower [50]. In the case of the miR-9*, the same result was reported by Nisenblat et al. [42] in 2019.
Jia et al. (2013) performed a miRNA microarray analysis and demonstrated that plasma levels of miR-17-5p, miR-20a, and miR-22 were downregulated in endometriosis patients [49]. In another study, Bashti et al. collected plasma samples from women with or without endometriosis and analyzed them using the qRT-PCR technique to compare the expression levels of miR-145 and miR-31. They found that miR-31 was downregulated while miR-145 was upregulated significantly in women with endometriosis [51]. In addition, altered serum levels of let-7b, let-7d, and let-7f during the proliferative phase were suggested as a diagnostic marker for endometriosis [35]. Furthermore, plasma levels of miR-200a and miR-141 were lower in endometriosis patients, suggesting them as potential novel noninvasive biomarkers for endometriosis [32][47]. It is worth noting that evaluating two or more biomarkers at the same time increases the prognostic value [32]. Vanhi et al. [33] conducted a genome-wide miRNA expression profiling to determine a group of plasma miRNAs that can distinguish between endometriosis and non-endometriosis patients. They identified 42 miRNAs, but only one panel comprising hsa-miR-125b-5p, hsa-miR-28-5p, and hsa-miR-29a-3p with intermediate sensitivity (78%) but low specificity (37%), showed diagnostic power.

3. The Role of miR-200 Family Members in Endometriosis

The miR-200 family of miRNAs consists of five evolutionary conserved members, namely, miR-200a, miR-200b, miR-429, miR-200c, and miR-141, which are encoded in two clusters of hairpin precursors on human chromosomes 1 (miR-200b/a and miR-429) and 12 (miR-200c and miR-141) [52]. These miRNAs not only play roles in tumor development, angiogenesis, and metastasis, but they also regulate some vital biological processes such as cellular transformation, cell proliferation, drug resistance, and epithelial-mesenchymal transition (EMT) (Figure 2) [41][47][53].
Figure 2. The miR-200 family regulates epithelial-mesenchymal transition (EMT). Biomedicines 10 02558 i001: Inhibition, Biomedicines 10 02558 i002: Stimulation.

References

  1. Giudice, L.C.; Kao, L.C. Endometriosis. Lancet 2004, 364, 1789–1799.
  2. Nezhat, C.; Falik, R.; McKinney, S.; King, L.P. Pathophysiology and management of urinary tract endometriosis. Nat. Rev. Urol. 2017, 14, 359–372.
  3. Florova, M.S.; Yarmolinskaya, M.I.; Potin, V.V. Prospects of metformin in the treatment of endometriosis. J. Obstet. Women’s Dis. 2017, 66, 67–76.
  4. Smolarz, B.; Szyłło, K.; Romanowicz, H. Endometriosis: Epidemiology, Classification, Pathogenesis, Treatment and Genetics (Review of Literature). Int. J. Mol. Sci. 2021, 22, 10554.
  5. Cheng, J.; Li, C.; Ying, Y.; Lv, J.; Qu, X.; McGowan, E.; Lin, Y.; Zhu, X. Metformin Alleviates Endometriosis and Potentiates Endometrial Receptivity via Decreasing VEGF and MMP9 and Increasing Leukemia Inhibitor Factor and HOXA10. Front. Pharmacol. 2022, 13, 501.
  6. Di Guardo, F.; Shah, M.; Cerana, M.C.; Biondi, A.; Karaman, E.; Török, P.; Yela, D.A.; Giampaolino, P.; Marín-Buck, A.; Laganà, A. Management of women affected by endometriosis: Are we stepping forward? J. Endometr. Pelvic Pain Disord. 2019, 11, 77–84.
  7. Nicolaus, K.; Reckenbeil, L.; Bräuer, D.; Sczesny, R.; Diebolder, H.; Runnebaum, I.B. Cycle-related Diarrhea and Dysmenorrhea are Independent Predictors of Peritoneal Endometriosis, Cycle-related Dyschezia is an Independent Predictor of Rectal Involvement. Geburtshilfe und Frauenheilkd. 2020, 80, 307–315.
  8. Alkatout, I.; Wedel, T.; Maass, N. Combined treatment of endometriosis: Radical yet gentle. Aktuelle Urol. 2018, 49, 60–72.
  9. Freytag, D.; Peters, G.; Mettler, L.; Gitas, G.; Maass, N.; Alkatout, I. Perioperative considerations in the treatment of endometriosis. J. Turk. Gynecol. Assoc. 2021, 22, 319–325.
  10. Mettler, L.; Ruprai, R.; Alkatout, I. Impact of Medical and Surgical Treatment of Endometriosis on the Cure of Endometriosis and Pain. BioMed Res. Int. 2014, 2014, 264653.
  11. Missmer, S.A.; Tu, F.F.; Agarwal, S.K.; Chapron, C.; Soliman, A.M.; Chiuve, S.; Eichner, S.; Flores-Caldera, I.; Horne, A.W.; Kimball, A.B.; et al. Impact of Endometriosis on Life-Course Potential: A Narrative Review. Int. J. Gen. Med. 2021, 14, 9–25.
  12. Facchin, F.; Barbara, G.; Dridi, D.; Alberico, D.; Buggio, L.; Somigliana, E.; Saita, E.; Vercellini, P. Mental health in women with endometriosis: Searching for predictors of psychological distress. Hum. Reprod. 2017, 32, 1855–1861.
  13. Matloobi, M.; Amini, L.; ShahAli, S.; Haghani, H.; Tahermanesh, K.; Hassanlouei, B.; Allahqoli, L.; Alkatout, I. Effect of sex education on sexual function and sexual quality of life in women with endometriosis: A quasi-experimental study. Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet. 2022.
  14. Kimball, A.B.; Gieler, U.; Linder, D.; Sampogna, F.; Warren, R.B.; Augustin, M. Psoriasis: Is the impairment to a patient’s life cumulative? J. Eur. Acad. Dermatol. Venereol. JEADV 2010, 24, 989–1004.
  15. Ballard, K.; Lowton, K.; Wright, J. What’s the delay? A qualitative study of women’s experiences of reaching a diagnosis of endometriosis. Fertil. Steril. 2006, 86, 1296–1301.
  16. Alkatout, I.; Meinhold-Heerlein, I.; Keckstein, J.; Mettler, L. Endometriosis: A concise practical guide to current diagnosis and treatment. J. Turk. Gynecol. Assoc. 2018, 19, 173–175.
  17. D’Hooghe, T.; Mihalyi, A.; Simsa, P.; Kyama, C.; Peeraer, K.; De Loecker, P.; Meeuwis, L.; Segal, L.; Meuleman, C. Why We Need a Noninvasive Diagnostic Test for Minimal to Mild Endometriosis with a High Sensitivity. Gynecol. Obstet. Investig. 2006, 62, 136–138.
  18. Leyland, N.; Casper, R.; Laberge, P.; Singh, S.S. Endometriosis: Diagnosis and management. J. Obstet. Gynaecol. Can. JOGC 2010, 32 (Suppl. 2), S1–S32.
  19. Mabrouk, M.; Raimondo, D.; Parisotto, M.; Del Forno, S.; Arena, A.; Seracchioli, R. Pelvic floor dysfunction at transperineal ultrasound and voiding alteration in women with posterior deep endometriosis. Int. Urogynecology J. 2019, 30, 1527–1532.
  20. Berker, B.; Seval, M. Problems with the Diagnosis of Endometriosis. Women’s Health 2015, 11, 597–601.
  21. Horne, A.W.; Daniels, J.; Hummelshoj, L.; Cox, E.; Cooper, K.G. Surgical removal of superficial peritoneal endometriosis for managing women with chronic pelvic pain: Time for a rethink? BJOG Int. J. Obstet. Gynaecol. 2019, 126, 1414–1416.
  22. Hudson, N. The missed disease? Endometriosis as an example of ‘undone science’. Reprod Biomed. Soc. Online 2022, 14, 20–27.
  23. Koninckx, P.R. Is mild endometriosis a condition occurring intermittently in all women? Hum. Reprod. 1994, 9, 2202–2205.
  24. Szubert, M.; Suzin, J.; Wierzbowski, T.; Kowalczyk-Amico, K. CA-125 concentration in serum and peritoneal fluid in patients with endometriosis–preliminary results. Arch. Med. Sci. 2012, 8, 504–508.
  25. Anastasi, E.; Manganaro, L.; Granato, T.; Benedetti Panici, P.; Frati, L.; Porpora, M.G. Is CA72-4 a useful biomarker in differential diagnosis between ovarian endometrioma and epithelial ovarian cancer? Dis. Markers 2013, 35, 331–335.
  26. Abrão, M.S.; Podgaec, S.; Pinotti, J.A.; de Oliveira, R.M. Tumor markers in endometriosis. Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet. 1999, 66, 19–22.
  27. Rokhgireh, S.; Kashi, A.M.; Chaichian, S.; Delbandi, A.-A.; Allahqoli, L.; Ahmadi-Pishkuhi, M.; Khodaverdi, S.; Alkatout, I. The Diagnostic Accuracy of Combined Enolase/Cr, CA125, and CA19-9 in the Detection of Endometriosis. BioMed Res. Int. 2020, 2020, 5208279.
  28. Telimaa, S.; Kauppila, A.; Rönnberg, L.; Suikkari, A.M.; Seppälä, M. Elevated serum levels of endometrial secretory protein PP14 in patients with advanced endometriosis. Suppression by treatment with danazol and high-dose medroxyprogesterone acetate. Am. J. Obstet. Gynecol. 1989, 161, 866–871.
  29. Medl, M.; Ogris, E.; Peters-Engl, C.; Mierau, M.; Buxbaum, P.; Leodolter, S. Serum levels of the tumour-associated trypsin inhibitor in patients with endometriosis. BJOG Int. J. Obstet. Gynaecol. 1997, 104, 78–81.
  30. Wahid, F.; Shehzad, A.; Khan, T.; Kim, Y.Y. MicroRNAs: Synthesis, mechanism, function, and recent clinical trials. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 2010, 1803, 1231–1243.
  31. Misir, S.; Hepokur, C.; Oksasoglu, B.; Yildiz, C.; Yanik, A.; Aliyazicioglu, Y. Circulating serum miR-200c and miR-34a-5p as diagnostic biomarkers for endometriosis. J. Gynecol. Obstet. Hum. Reprod. 2021, 50, 102092.
  32. La Ferlita, A.; Battaglia, R.; Andronico, F.; Caruso, S.; Cianci, A.; Purrello, M.; Di Pietro, C. Non-coding RNAs in endometrial physiopathology. Int. J. Mol. Sci. 2018, 19, 2120.
  33. Vanhie, A.O.D.; Peterse, D.; Beckers, A.; Cuéllar, A.; Fassbender, A.; Meuleman, C.; Mestdagh, P.; D’Hooghe, T. Plasma miRNAs as biomarkers for endometriosis. Hum. Reprod. 2019, 34, 1650–1660.
  34. Shu, J.; E Silva, B.V.R.; Gao, T.; Xu, Z.; Cui, J. Dynamic and Modularized MicroRNA Regulation and Its Implication in Human Cancers. Sci. Rep. 2017, 7, 13356.
  35. Cho, S.; Mutlu, L.; Grechukhina, O.; Taylor, H.S. Circulating microRNAs as potential biomarkers for endometriosis. Fertil. Steril. 2015, 103, 1252–1260.e1.
  36. Agrawal, S.; Tapmeier, T.T.; Rahmioglu, N.; Kirtley, S.; Zondervan, K.T.; Becker, C.M. The miRNA Mirage: How Close Are We to Finding a Non-Invasive Diagnostic Biomarker in Endometriosis? A Systematic Review. Int. J. Mol. Sci. 2018, 19, 599.
  37. Ohlsson Teague, E.M.C.; Print, C.G.; Hull, M.L. The role of microRNAs in endometriosis and associated reproductive conditions. Hum. Reprod. Update 2010, 16, 142–165.
  38. O’Carroll, D.; Schaefer, A. General Principals of miRNA Biogenesis and Regulation in the Brain. Neuropsychopharmacology 2013, 38, 39–54.
  39. Korpal, M.; Lee, E.S.; Hu, G.; Kang, Y. The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283, 14910–14914.
  40. Bendifallah, S.; Suisse, S.; Puchar, A.; Delbos, L.; Poilblanc, M.; Descamps, P.; Golfier, F.; Jornea, L.; Bouteiller, D.; Touboul, C.; et al. Salivary MicroRNA Signature for Diagnosis of Endometriosis. J. Clin. Med. 2022, 11, 612.
  41. Humphries, B.; Yang, C. The microRNA-200 family: Small molecules with novel roles in cancer development, progression and therapy. Oncotarget 2015, 6, 6472–6498.
  42. Nisenblat, V.; Sharkey, D.J.; Wang, Z.; Evans, S.F.; Healey, M.; Teague, E.M.C.O.; Print, C.G.; A Robertson, S.; Hull, M.L. Plasma miRNAs Display Limited Potential as Diagnostic Tools for Endometriosis. J. Clin. Endocrinol. Metab. 2019, 104, 1999–2022.
  43. Boils, A.B.; Marí-Alexandre, J.; Gilabert, J.; Sánchez-Izquierdo, D.; España, F.; Estellés, A.; Gilabert-Estellés, J. MicroRNA expression profile in endometriosis: Its relation to angiogenesis and fibrinolytic factors. Hum. Reprod. 2014, 29, 978–988.
  44. Ohlsson Teague, E.M.C.; Van der Hoek, K.H.; Van der Hoek, M.B.; Perry, N.; Wagaarachchi, P.; Robertson, S.A.; Print, C.G.; Hull, L.M. MicroRNA-regulated pathways associated with endometriosis. Mol. Endocrinol. 2009, 23, 265–275.
  45. Gao, S.; Liu, S.; Gao, Z.-M.; Deng, P.; Wang, D.-B. Reduced microRNA-451 expression in eutopic endometrium contributes to the pathogenesis of endometriosis. World J. Clin. Cases 2019, 7, 2155–2164.
  46. Moustafa, S.; Burn, M.; Mamillapalli, R.; Nematian, S.; Flores, V.; Taylor, H.S. Accurate diagnosis of endometriosis using serum microRNAs. Am. J. Obstet. Gynecol. 2020, 223, 557.e1–557.e11.
  47. Rekker, K.; Saare, M.; Roost, A.M.; Kaart, T.; Sõritsa, D.; Karro, H.; Sõritsa, A.; Simón, C.; Salumets, A.; Peters, M. Circulating miR-200–family micro-RNAs have altered plasma levels in patients with endometriosis and vary with blood collection time. Fertil. Steril. 2015, 104, 938–946.e2.
  48. Bendifallah, S.; Dabi, Y.; Suisse, S.; Jornea, L.; Bouteiller, D.; Touboul, C.; Puchar, A.; Daraï, E. MicroRNome analysis generates a blood-based signature for endometriosis. Sci. Rep. 2022, 12, 4051.
  49. Jia, S.Z.; Yang, Y.; Lang, J.; Sun, P.; Leng, J. Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis. Hum. Reprod. 2013, 28, 322–330.
  50. Wang, W.-T.; Zhao, Y.-N.; Han, B.-W.; Hong, S.-J.; Chen, Y.-Q. Circulating MicroRNAs Identified in a Genome-Wide Serum MicroRNA Expression Analysis as Noninvasive Biomarkers for Endometriosis. J. Clin. Endocrinol. Metab. 2013, 98, 281–289.
  51. Bashti, O.; Noruzinia, M.; Garshasbi, M.; Abtahi, M. miR-31 and miR-145 as potential non-invasive regulatory biomarkers in patients with endometriosis. Cell J. 2018, 20, 84.
  52. Cavallari, I.; Ciccarese, F.; Sharova, E.; Urso, L.; Raimondi, V.; Silic-Benussi, M.; D’Agostino, D.M.; Ciminale, V. The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers. Cancers 2021, 13, 5874.
  53. Kong, D.; Li, Y.; Wang, Z.; Banerjee, S.; Ahmad, A.; Kim, H.R.C.; Sarkar, F.H. miR-200 regulates PDGF-D-mediated epithelial–mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009, 27, 1712–1721.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Obstetrics & Gynaecology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Fahimeh Ghasemi
,
Effat Alemzadeh
, Leila Allahqoli ,
Esmat Alemzadeh
,
Afrooz Mazidimoradi
, Hamid Salehiniya , Ibrahim Alkatout
View Times: 834
Revisions: 2 times (View History)
Update Date: 18 Oct 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    Academic Video Service
    Feedback